Bevacizumab: Anti-VEGF monoclonal antibody, avastin, rhumab-VEGF

被引：0
|
作者：
不详
机构：
来源：
Drugs in R & D | 2002年 / 3卷 / 1期
关键词：
Bevacizumab; Irinotecan; Metastatic Breast Cancer; Folinic Acid; Retinal Vein Occlusion;
D O I：
10.2165/00126839-200203010-00006
中图分类号：
学科分类号：
摘要：
[No abstract available]
引用
收藏
页码：28 / 30
页数：2
相关论文
共 50 条
  • [41] Phase I study of anti-VEGF monoclonal antibody bevacizumab and histone deacetylase inhibitor valproic acid in patients with advanced cancers
    Wheler, Jennifer J.
    Janku, Filip
    Falchook, Gerald S.
    Jackson, Tiffiny L.
    Fu, Siqing
    Naing, Aung
    Tsimberidou, Apostalia M.
    Moulder, Stacy L.
    Hong, David S.
    Yang, Hui
    Piha-Paul, Sarina A.
    Atkins, Johnique T.
    Garcia-Manero, Guillermo
    Kurzrock, Razelle
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2014, 73 (03) : 495 - 501
  • [42] Phase I study of anti-VEGF monoclonal antibody bevacizumab and histone deacetylase inhibitor valproic acid in patients with advanced cancers
    Jennifer J. Wheler
    Filip Janku
    Gerald S. Falchook
    Tiffiny L. Jackson
    Siqing Fu
    Aung Naing
    Apostalia M. Tsimberidou
    Stacy L. Moulder
    David S. Hong
    Hui Yang
    Sarina A. Piha-Paul
    Johnique T. Atkins
    Guillermo Garcia-Manero
    Razelle Kurzrock
    Cancer Chemotherapy and Pharmacology, 2014, 73 : 495 - 501
  • [43] Thiol modification of bevacizumab, an anti-VEGF monoclonal antibody: labeling with Technetium-99m and initial in vitro and in vivo studies
    Bouziotis, P.
    Gourni, E.
    Harris, A. L.
    Loudos, G.
    Sakellios, N.
    Livaniou, E.
    Paravatou, M.
    Xanthopoulos, S.
    Archimandritis, S.
    Varvarigou, A. D.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2007, 34 : S260 - S260
  • [44] Cardiac Toxicity Associated with the Anti-VEGF Monoclonal Antibody Bevacizumab (Avastin) in Combination with CROP (A-CHOP) Chemotherapy for Peripheral T Cell Lymphoma (PTCL): The ECOG 2404 Trial.
    Advani, Ranjana H.
    Hong, Fangxin
    Ganjoo, Kristen N.
    Manola, Judith B.
    Swinnen, Lode J.
    Habermann, Thomas M.
    Horning, Sandra J.
    BLOOD, 2009, 114 (22) : 667 - 667
  • [45] Commentary on "Humanization of an Anti-VEGF Monoclonal Antibody for the Therapy of Solid Tumors and Other Disorders"
    Ferrara, Napoleone
    CANCER RESEARCH, 2016, 76 (17) : 4913 - 4915
  • [46] Preclinical pharmacokinetics of a recombinant humanized rabbit anti-VEGF monoclonal antibody in rabbits and monkeys
    Yu, Dong-An
    You, Meng
    Ji, Wan-Wan
    Lu, You
    Liu, Bin
    Yan, Shou-Sheng
    TOXICOLOGY LETTERS, 2018, 292 : 73 - 77
  • [47] Failure of Treatment with Anti-VEGF Monoclonal Antibody for Long-standing POEMS Syndrome
    Kanai, Kazuaki
    Kuwabara, Satoshi
    Misawa, Sonoko
    Hattori, Takamichi
    INTERNAL MEDICINE, 2007, 46 (06) : 311 - 313
  • [48] Ranibizumab and bevacizumab as anti-vegf ocular treatment: a safety review
    Therasse, C.
    Martinez, L.
    Ginisty, S.
    Horowicz, S.
    Eftekhari, P.
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2013, 27 : 61 - 61
  • [49] Bevacizumab: direct anti-VEGF therapy in renal cell carcinoma
    Escudier, Bernard
    Cosaert, Jan
    Pisa, Pavel
    EXPERT REVIEW OF ANTICANCER THERAPY, 2008, 8 (10) : 1545 - 1557
  • [50] Does anti-VEGF bevacizumab improve survival in experimental sepsis?
    Emmanuel Besnier
    Ebba Brakenhielm
    Vincent Richard
    Fabienne Tamion
    Critical Care, 21
12345